ALS TDI Announces Research Agreement with Biogen Idec and UCB

The nonprofit biotech, ALS Therapy Development Institute has formed a new partnership with Biogen Idec and UCB to further the development of compounds targeting the CD40 Ligand pathway in ALS. The terms of the agreement call for TDI to perform preclinical testing, in the SOD1 model, of a murine surrogate of CDP7657, a anti-CD40L biologic that UCB is currently clinically exploring in systemic lupus erythematosus in a phase I trial. As this partnership signals, immunomodulation could be a very promising therapeutic area for ALS, one which may greatly benefit from several current industry-led efforts to develop immunomodulatory drugs for multiple sclerosis (discussed in Nature Reviews Drug Discovery: http://www.nature.com/nrd/journal/v10/n12/full/nrd3610.html).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail